ONDANSETRON Drug Patent Profile
✉ Email this page to a colleague
When do Ondansetron patents expire, and what generic alternatives are available?
Ondansetron is a drug marketed by Aurobindo Pharma, Barr, Chartwell Molecules, Glenmark Generics, Ipca Labs Ltd, Mylan, Nesher Pharms, Sandoz, Sun Pharm Inds, Sun Pharm Inds Ltd, Teva, Accord Hlthcare, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Steriscience, Sun Pharm Inds (in), Wockhardt, Amneal Pharms, Pharm Assoc, Taro, Apotex, Casi Pharms Inc, Dr Reddys Labs Ltd, Hikma Intl Pharms, Natco Pharma Ltd, Am Regent, and Taro Pharms Ireland. and is included in seventy-nine NDAs.
The generic ingredient in ONDANSETRON is ondansetron hydrochloride. There are twenty-eight drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the ondansetron hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ondansetron
A generic version of ONDANSETRON was approved as ondansetron hydrochloride by FRESENIUS KABI USA on December 26th, 2006.
Summary for ONDANSETRON
Recent Clinical Trials for ONDANSETRON
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 4 |
Genuine Research Center, Egypt | Phase 3 |
Adwia Pharma, Egypt | Phase 3 |
Pharmacology for ONDANSETRON
Drug Class | Serotonin-3 Receptor Antagonist |
Mechanism of Action | Serotonin 3 Receptor Antagonists |